PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system

PacBio (NASDAQ:PACB) announced the upcoming SPRQ-Nx chemistry and a software update for its Vega sequencing system, raising per-run HiFi output from 60 Gb to 90 Gb and lowering the U.S. list price per run from $1,100 to $995.

Rhea-AI Summary

PacBio (NASDAQ:PACB) announced the upcoming SPRQ-Nx chemistry and a software update for its Vega sequencing system, raising per-run HiFi output from 60 Gb to 90 Gb and lowering the U.S. list price per run from $1,100 to $995. This combination reduces cost per gigabase by about 40% and enables more samples per run across whole-genome, targeted, and synthetic biology applications.

The software update adds two-hour and four-hour runs, new and improved DNA methylation callers (5hmC, 5mC, 6mA), and user login and audit-tracking features to support 21 CFR Part 11 compliance. DNA input requirements drop from 2 µg to as low as 500 ng, and labs can multiplex up to 96 samples per run. PacBio expects chemistry and software availability by the end of the month.

Positive

• HiFi output per run increased from 60 Gb to 90 Gb
• U.S. list price per run cut from $1,100 to $995
• Cost per gigabase lowered by approximately 40%
• DNA input requirement reduced from 2 µg to as low as 500 ng
• Throughput up to 96 samples per run with PureTarget panels
• New short run times of two and four hours for Vega

Negative

• None.

News Explained

PacBio plans to ship the Vega SPRQ-Nx update by month-end; its disclosed first-half 2026 run mix—19% of Vega runs using sub-2-kb inserts versus 3.6% on Revio—supports fitting these faster options within a single laboratory shift.

Argus Aug 5 session 29 alerts

-9.72% close to close 1.9x rel. volume Open Argus

Details

News Market Reaction – PACB

-16.7% Trough in 20 hr 57 min

$438.67M Market Cap

In the Aug 5 session, PACB declined 9.72%, reflecting a notable negative market reaction. Argus tracked a trough of -16.7% from its starting point during tracking. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -9.7% in the session following this news. PacBio’s prior clinical-study announcement...

Analysis

The stock moved -9.7% in the session following this news. PacBio’s prior clinical-study announcement was followed by a -3.9% 24-hour price reaction. A negative scenario would put greater weight on adoption and execution, with the active S-3ASR shelf remaining relevant financing context.

Key Figures

HiFi output: 60 Gb to 90 Gb per run U.S. list price: $1,100 to $995 per run Cost per gigabase: Approximately 40% lower +4 more

HiFi output

60 Gb to 90 Gb per run

Vega SPRQ-Nx chemistry

U.S. list price

$1,100 to $995 per run

Vega SPRQ-Nx chemistry

Cost per gigabase

Approximately 40% lower

Vega SPRQ-Nx chemistry

Sequencing runs

Two-hour and four-hour runs

Vega software update

Short-insert Vega runs

19% versus 3.6%

First half of 2026 Vega versus Revio runs

DNA input requirement

2 µg to as low as 500 ng

Vega SPRQ-Nx chemistry

Multiplex capacity

Up to 96 samples per run

PacBio PureTarget panels

Historical Context

5 past events · Latest: Jul 15

5 events

1. Jul 15

   earnings scheduling notice

   24h Move

   -2.6%

   Company scheduled its second-quarter 2026 financial results conference call.

2. May 26

   chemistry shipping announcement

   24h Move

   +3.3%

   SPRQ-Nx began worldwide shipping with lower sequencing costs and sub-$300 genome target.

3. May 21

   conference participation

   24h Move

   -2.4%

   Management announced participation in the Jefferies Global Healthcare Conference.

4. May 19

   strategic collaboration

   24h Move

   +0.0%

   PacBio collaborated with Blank Bio following a $7.2 million seed financing.

5. May 11

   clinical study results

   24h Move

   -3.9%

   Consortium study reported genomic findings in subfertility and recurrent pregnancy loss.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

5-hydroxymethylcytosine (5hmC), 5mC, 21 CFR Part 11

3 terms

5-hydroxymethylcytosine (5hmC) medical

"new 5-hydroxymethylcytosine (5hmC) caller"

5-hydroxymethylcytosine (5hmC) is a chemical modification of DNA that acts as an epigenetic mark, created when the methyl group on cytosine is oxidized. It helps regulate which genes are turned on or off without changing the underlying genetic code, like a sticky note on a page indicating which passages to read. Investors encounter 5hmC as a potential biomarker for disease detection and a target or readout in drug and diagnostic development.

5mC medical

"improved 5mC and 6mA callers"

5mC (5‑methylcytosine) is a chemical change to DNA where a small methyl group attaches to the fifth carbon of the cytosine base, altering how that gene is read without changing the underlying genetic code. It matters to investors because patterns of 5mC are used as biomarkers in diagnostics, drug development, and epigenetic research—think of it like sticky notes added to a book that change how chapters are interpreted and can signal disease or treatment response.

21 CFR Part 11 regulatory

"support customers’ 21 CFR Part 11 compliance efforts"

21 CFR Part 11 is a U.S. regulatory rule that sets requirements for how electronic records and electronic signatures must be created, stored and protected so they can be trusted as if they were paper documents. For investors, it matters because companies that handle regulated data—like clinical trial results or manufacturing logs—must meet these controls or face regulatory delays, fines or lost market access; think of it as a lock-and-audit trail for digital paperwork.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Vega SPRQ-Nx chemistry to deliver up to 90 Gb per run at 40% lower cost per gigabase, with single-shift runs and new workflow controls for regulated labs

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced the upcoming availability of SPRQ-Nx chemistry and an accompanying software update for its Vega systems. Together, the updates expand the range of HiFi applications laboratories can run in-house and allow customers to match sequencing performance and run time to specific project needs.

Vega SPRQ-Nx brings the same core chemistry used on the high-throughput Revio system to Vega, increasing output from 60 Gb to 90 Gb of HiFi data per run. PacBio is also lowering the U.S. list price per run from $1,100 to $995. The higher output and lower price per run lowers cost per Gb by approximately 40%, letting laboratories run more samples across whole-genome sequencing, targeted sequencing, and synthetic biology applications.

Alongside the new chemistry, the Vega software update introduces two-hour and four-hour sequencing runs. The update also brings Vega in line with the multiomic analysis capabilities available on Revio with a new 5-hydroxymethylcytosine (5hmC) caller and improved 5mC and 6mA callers. Finally, the update adds user login and audit-tracking capabilities designed to support customers’ 21 CFR Part 11 compliance efforts and strengthen data integrity and workflow traceability.

"Vega SPRQ-Nx expands what labs can do on a benchtop HiFi system,” said Christian Henry, President and CEO of PacBio. “Customers get 50% more HiFi data at a lower price per run, along with faster sequencing options, richer DNA-methylation insights, and controls designed for regulated workflows. These advances and cost reductions make it practical to bring many more high-value HiFi applications in-house or for labs to adopt HiFi sequencing for the first time.”

In the first half of 2026, 19% of Vega runs used libraries with inserts shorter than 2 kb, compared with 3.6% of Revio runs, illustrating Vega’s distinct role in targeted and other short-insert workflows. While Revio customers primarily run whole-genome and full-length RNA sequencing, Vega customers are using the benchtop system across a broad mix of short-insert applications. The new sequencing options allow these short-insert runs to complete within a single laboratory shift, helping keep projects moving.

Vega SPRQ-Nx chemistry lowers DNA input requirements from 2 µg to as low as 500 ng, up to a fourfold reduction that gives laboratories greater flexibility with limited samples and broadens the range of projects they can run in-house. The higher yield also enables laboratories to multiplex up to 96 samples per run using PacBio PureTarget repeat expansion and carrier screening panels, increasing throughput and lowering per-sample sequencing costs.

PacBio plans to make the Vega SPRQ-Nx chemistry products available to ship, and the accompanying Vega software update available to download, by the end of the month. For specifications and ordering information, visit www.pacb.com/vega.

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.   

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.   

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, including in connection with the planned Vega SPRQ-Nx sequencing chemistry and updated software; reduction in sequencing costs by as much as 40%; improved workflow controls and support for customers’ compliance efforts, data integrity and workflow traceability; improved methylation calling and epigenetic insight; increase in HiFi data by up to 50%; anticipated lower U.S. list prices; laboratories being able to run more samples across more applications; two- and four-hour sequencing runs; potential increased practicality of customers to bring more high-value HiFi applications in-house or to adopt HiFi sequencing for the first time; lower DNA input requirements; potential increased throughput; planned release time-frame; and other forward-looking statements. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in developing, manufacturing, launching, marketing and selling new products; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses, including in connection with increased chip and memory costs; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products; potential product performance and quality issues; the possible loss of key suppliers; and, third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.

Contacts
Investors:
Jim Gibson: jamesgibson@pacb.com or ir@pacificbiosciences.com
Media:
pr@pacificbiosciences.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is PacBio’s Vega SPRQ-Nx chemistry and how does it change HiFi output for PACB?

Vega SPRQ-Nx is a new chemistry that raises Vega HiFi output from 60 Gb to 90 Gb per run. According to PacBio, it uses the same core chemistry as Revio, broadening in-house HiFi applications on the benchtop platform.

How much does PacBio’s Vega SPRQ-Nx reduce sequencing cost per gigabase for PACB customers?

PacBio states that Vega SPRQ-Nx and pricing changes lower cost per gigabase by about 40%. This comes from boosting output to 90 Gb per run and reducing the U.S. list price per run from $1,100 to $995.

What new run times and workflow features are coming to the PacBio Vega system in August 2026?

According to PacBio, the Vega software update will introduce two-hour and four-hour sequencing runs. It will also add user login and audit-tracking capabilities to support 21 CFR Part 11 compliance and improve workflow traceability in regulated laboratories.

How does Vega SPRQ-Nx change DNA input requirements and sample multiplexing on PacBio’s Vega system (PACB)?

Vega SPRQ-Nx lowers DNA input from 2 µg to as low as 500 ng per run. According to PacBio, higher yield also lets labs multiplex up to 96 samples using PureTarget repeat expansion and carrier screening panels, reducing per-sample costs.

When will PacBio’s Vega SPRQ-Nx chemistry and software update be available for PACB investors to track adoption?

PacBio plans to make Vega SPRQ-Nx chemistry available to ship and the Vega software update available to download by the end of the month. Investors can monitor adoption as labs expand HiFi applications in-house using these enhanced capabilities.

What new methylation analysis capabilities will PacBio’s Vega system gain with the SPRQ-Nx update?

According to PacBio, the Vega software update adds a new 5-hydroxymethylcytosine (5hmC) caller and improves 5mC and 6mA callers. These changes bring Vega’s multiomic analysis capabilities in line with Revio for richer DNA-methylation insights.